Subscribe Sign in

Health

CSL acknowledges "disappointing" results but aims to do better

1 min read Rewritten in plain language

Healthcare Shares

Show what we removed Rules applied: A1×4 A6 D2 D3×7 E3×4 F2×2 all 30 rules
  • CSL Ltd's board has admitted the financial performance of the business has been disappointing, but vowed to do better ahead of the company's upcoming annual general meeting.
  • We recognise this, and the management team is acting with urgency to earn back the confidence of shareholders through results.
  • CSL shares were 1 cent lower at $174.40 on Thursday.

3 sentences from our version of the report, chosen to cover it. Nothing here is written; every line is in the article below. How

CSL Ltd's board has admitted the financial performance of the business has been disappointing, but vowed to do better ahead of the company's upcoming annual general meeting.

The report’s most important sentence, shortened and in plain words. How

Headline check

The one thing this headline claims is in the report.

Figures, names and quoted words in the headline, looked for in the report itself — not in the summary above. One claim in this headline could be checked, so this is a narrow pass and not a thorough one. How this is checked

CSL Ltd's board has admitted the financial performance of the business has been disappointing, but vowed to do better ahead of the company's upcoming annual general meeting.

In the notice of meeting lodged with the ASX, CSL chair Brian McNamee said the past year had been one of "significant change" for the blood products company, "and the board acknowledges that many shareholders are frustrated with the recent disappointing commercial and financial performance of the company''."

We recognise this, and the management team is acting with urgency to earn back the confidence of shareholders through results.

Mr McNamee said the company's core markets remained attractive, and the business was resilient and delivering strong cash flows.

Mr McNamee said the board was encouraged by the early positive results of changes carried out by the management team.

CSL shares were 1 cent lower at $174.40 on Thursday.

Brokers are now positive on the outlook for CSL following the company's August results release.

Shortened to 1 minute of reading, this version reads 7.2 on the Niral Score.

You are reading our version, not theirs. This is The Motley Fool Australia's report shortened to its most important sentences, in plainer words, with verdicts and loaded words taken out. Plain description stays, and so do adjectives that carry a fact, such as "former" or "federal". The reporting, the facts and the quotations are theirs — quotations are never edited — and the indicators beside it measure this version. Hover or tap Adjectives to see every one left in the text.

How this outlet filed it, and how we rewrote it

No other newsroom we read has filed on this event, so there is nothing to compare it with yet.

Outlet Niral ScoreAdjectivesSourcingSentimentHappiness
The Motley Fool Australiaas they published this story 12 14 69 0.3 52.7
Mundane Readneutralized from The Motley Fool Australia 8.2 10 69 0.3 52.7

Sign in to react.

Comments

Nothing here yet.

Sign in to comment.

Questions

Readers can ask a question about this story here. Questions and answers are for subscribers. Sign in to read them.

Comments are read before they appear where anything in them needs a person to look. Nothing posted here is ever deleted; a comment taken down keeps its text and the reason, so the decision can be looked at again. How this works